
Squishing spotted lanternflies isn't enough to eradicate the invasive insects. Here's what else you can do.
They are making a big comeback this summer and experts say there is a lot more you can do than just squish them to help end the threat.
It may feel like you're helping, but experts say stomping on spotted lanternflies is no longer enough. They have been spotted nearly everywhere on Long Island this month, with many residents telling CBS News New York they have seen the insects in cars, on streets, on lawns, and even on themselves.
Brittany Champey, with Spadefoot Design and Construction, says to halt the lanternflies' relentless attack on trees people need to rip out the invasive species or weeds they feed on.
"If you really want to make a difference, you have to go where they are congregating," Champney said. "The biggest impact any person can make is doing invasive species removal."
Champney says to take stock of what's growing in your yard.
"Everybody should take a look at their backyards, which of these invasive species do they have, and how can they remove them because that directly impacts the lanternfly population," she said.
That's what Spadefoot did on the grounds of the Science Museum of Long Island, replacing invasive with native plants. But in areas where invasive weeds still grow, armies of lanternflies are prevalent and about to grow wings.
The insects, native to China, were first seen in the U.S. in 2014. They literally suck the sap out of 100 of our plant species, including grape vines.
"Once an infestation takes over a winery they can reduce the crop by 90% or more in just one season," Champney said.
They lay their eggs of the Tree of Heaven trees, and experts say those especially should be ripped out.
"When the spotted lanternfly has access to that Tree of Heaven, that weedy species, it can lay seven times the number of eggs," said Brian Eschenaur of the Cornell Integrative Pest Management Program.
Eschenaur says along with ripping out Tree of Heaven plants in your yard, you should buy or build traps with fly paper bags and even suck the insects up with a vacuum.
"Take that Shop-Vac outside. That can be very effective," Eschenaur said.
Another thing the public can do is check cars to make sure motorists are not giving the bugs a lift out East, where Long Island vineyards are on high alert. Lanternflies have already been spotted in the Finger Lakes wine region.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
2 hours ago
- Yahoo
Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102
Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the . On April 14, Verve Therapeutics, Inc. (NASDAQ:VERV) reported results from its Heart-2 Phase 1b trial for VERVE-102. The trial focused on treating people with heterozygous familial hypercholesterolemia or early heart disease. Such patients need to lower their LDL cholesterol levels for a long time. Management noted that 14 participants received VERVE-102 at different doses, and the treatment was marked safe as there were no serious side effects connected to the drug and no important lab problems were seen. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting. The results showed that a single infusion of VERVE-102 reduced a key blood protein and significantly dropped LDL cholesterol. The reduction was dependent on the dose, with a mean reduction of 53% and a maximum reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort. Management believes that these results are promising, as a single dose can offer long-lasting reduction in LDL cholesterol. Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company developing genetic medicines for cardiovascular disease. Their treatments aim to provide long-lasting effects with a single gene-editing therapy instead of ongoing medication. While we acknowledge the potential of VERV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.


CBS News
2 hours ago
- CBS News
AI summit coming to Pittsburgh later this year will be headlined by Gov. Shapiro, Sen. McCormick
Governor Josh Shapiro and Pennsylvania Senator Dave McCormick will be headlining an AI summit in Pittsburgh later this year. AI Horizons 2025 will be held on September 11 and September 12 in the city's Bakery Square and is expected to "shine a spotlight on systems that interact with the real world through robotics, autonomy, simulation, and embedded AI." "From steel to AI, Pittsburgh has always built what the world needs next," said Joanna Doven, Executive Director of the AI Strike Team. "With deep industrial roots, top-tier research institutions, and bipartisan leadership, we are positioned to become the Physical AI capital of the world. AI Horizons is where that vision becomes action." The event will get underway on September 10 when more than $100,000 in prize money will be given out to startups in a competition. In addition to Gov. Shapiro and Sen. McCormick, executives from the tech community including Gecko Robotics and Skild AI are expected to be in attendance. The September summit announcement comes on the heels of the Inaugural Pennsylvania Energy and Innovation Summit at Carnegie Mellon University where President Trump and many leaders of the country's largest technology and energy companies announced more than $90 billion in new investments from private companies in Pennsylvania. "We don't just research AI here—we build it, deploy it, and power it," Doven said. "This is the next generation of industry, and just like we led with steel, we can lead again with AI." The full agenda and list of speakers is expected to be released early next month.